- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
Genomic Testing Cooperative is a private, innovation-driven clinical laboratory focused on comprehensive molecular profiling for hematologic and solid tumors. By combining DNA and RNA next-generation sequencing, advanced bioinformatics, machine learning, and deep clinical expertise, GTC supports physicians and institutions with clinically meaningful insights that can help expand precision medicine options for patients.
Genomic Testing Cooperative is a private, innovation-driven clinical laboratory focused on comprehensive molecular profiling for hematologic and solid tumors. By combining DNA and RNA next-generation sequencing, advanced bioinformatics, machine learning, and deep clinical expertise, GTC supports physicians and institutions with clinically meaningful insights that can help expand precision medicine options for patients.
GTC’s growth is supported by a multidisciplinary team with experience in molecular pathology, hematopathology, bioinformatics, laboratory operations, commercial development, and clinical innovation. The company’s cooperative-based model is designed to support scalable testing, collaborative data development, and broader access to advanced molecular diagnostics.
GTC is focused on tumor profiling using next-generation sequencing to analyze DNA and RNA from hematologic and solid tumors. This integrated approach allows GTC to support a broad range of clinical applications, including diagnosis, disease classification, prognosis, therapy selection, biomarker interpretation, and clinical trial matching.
The company has developed proprietary interpretation software that uses advanced bioinformatics and machine learning to help analyze complex molecular data and support more efficient interpretation of genomic findings. This combination of laboratory expertise, technology, and clinical insight is central to GTC’s approach to precision oncology.
GTC’s investor opportunity is grounded in a real clinical need: the growing demand for high-quality, clinically actionable molecular testing in oncology. As cancer care becomes increasingly guided by genomic and transcriptomic information, laboratories, physicians, health systems, and patients need testing solutions that are comprehensive, scalable, and clinically relevant.
Key strengths include:
As a fast-growing private company, GTC may consider outside investment to support continued growth, technology development, laboratory expansion, market reach, and strategic initiatives. Company valuation and investment opportunities are evaluated in the context of revenue, market position, industry landscape, growth potential, and comparable market multiples.
